Advanced Biophysical Analysis Reveals Critical Differences in Leading Lipid Nanoparticle Formulations
A detailed biophysical analysis of four leading lipid nanoparticle formulations reveals crucial differences in structure and performance. The study demonstrates how manufacturing methods significantly impact LNP characteristics and therapeutic potential.
Comparative Analysis of Clinically Significant Lipid Nanoparticles
Researchers have conducted an extensive biophysical characterization of four clinically important lipid nanoparticle (LNP) formulations, according to reports published in Nature Biotechnology. The study compared LNPs containing ionizable lipids MC3 (used in Alnylam’s Onpattro), C12-200 (academic standard), SM-102 (Moderna’s Spikevax), and ALC-0315 (Pfizer/BioNTech’s Comirnaty), all prepared with modified mRNA encoding firefly luciferase.